Post by Novo Nordisk

We are presenting 52 new abstracts on obesity treatment at the 2026 European Congress on Obesity. This demonstrates the broadest portfolio of approved and pipeline GLP-1-based therapies. Our new clinical and real-world data is being presented in Istanbul, Türkiye from 12–15 May. Learn more in the press release here: https://lnkd.in/eTyMPAwc #PRESS